A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events
Titel:
A multi-center comparative study of Atezolizumab plus Bevacivumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma (HCC): focus on thrombotic and hemorrhagic adverse events
Auteur:
Tizzani, M. Mazzarelli, C. Burlone, M. Carucci, P. Caviglia, G.P. Lisi, C. Canalis, C. Cesarini, L. Pirisi, M. Acquaviva, A. Rolle, E. Pochettino, P. Bencardino, K. Villa, F. Angiolillo, M. Scaldaferri, M. Castellana, E. Cattel, F. Airoldi, M. Saracco, G.M. Gaia, S.